nChroma Bio is a clinical-stage genetic medicines company developing engineered epigenetic silencers to overcome the limitations of existing therapies and enable next-generation genomic medicines. By combining in vivo delivery and gene-regulating technologies, nChroma is designing optimal solutions to deliver precise, potent and durable treatments for patients with high unmet needs. nChroma’s lead candidate, CRMA-1001, is a clinical-stage, liver-directed epigenetic silencer in development as a potential functional cure for chronic hepatitis B. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, nChroma is redefining targeted in vivo genetic medicine with the initial goal of treating diseases affecting the liver, blood, cardiovascular and central nervous systems.

nChroma Bio

Org chart

Teams

Offices